dual gip/glp-1 receptor agonist The Sustained Effects of a Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Tirzepatide, a dual GIP/GLP-1 receptor
Description
Poston L, Caleyachetty R, Cnattingius S, Corvaln C, Uauy R, Herring S, Gillman MW
Among them, gastrointestinal adverse reactions mainly occurred in the early stage of the first drug use, with mild to moderate degrees (109)
Skov J, Dejgaard A, Frkir J, et al
Thats a significantly higher percentage than most other non-surgical weight loss treatments
[Google Scholar] 15.Fodden J.H., Read W.O
